Anovulatory infertility is common in polycystic ovary syndrome (PCOS). Clinicians who provide first-line treatment have to decide how best to induce ovulation with the desired outcome of live birth, a decision often complicated by the phenotypic heterogeneity of PCOS. could a new livebirth prediction model of different ovulation induction methods developed from basic clinical parameters help select infertility treatments?
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/nrendo.2009.251 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A retrospective analysis on maternal and neonatal outcomes in pSS/AITD pregnancies.
Sci Rep
January 2025
Department of Obstetrics, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint Laboratory of Maternal-Fetal Medicine, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510150, China.
The combined impact of concurrent primary Sjögren's syndrome (pSS) and autoimmune thyroid disease (AITD) on pregnancy outcomes remains underreported. A retrospective analysis was conducted on 115 pregnant patients diagnosed with pSS and delivering at the Third Affiliated Hospital of Guangzhou Medical University from January 2009 to July 2023. The effects of AITD on maternal and neonatal outcomes were examined and compared to a control group without AITD.
View Article and Find Full Text PDFOptimal aspiration pressure of suction pump for oocyte retrieval in infertile patients undergoing in vitro fertilization.
PLoS One
January 2025
Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, South Korea.
Background: The oocyte retrieval is a critical step in assisted reproductive technologies, including in vitro fertilization and fertility preservation. Despite evolving techniques, the optimal aspiration pressure during retrieval remains debatable, with limited in vivo human studies. Existing studies, primarily in vitro and on animals, suggest that inappropriate aspiration pressures can impair oocyte quality.
View Article and Find Full Text PDFThe dilemma of X-linked agammaglobulinemia carriers.
J Allergy Clin Immunol Glob
February 2025
Department of Molecular Medicine, Sapienza University, Rome, Italy.
Background: Many patients with X-linked agammaglobulinemia (XLA) nowadays have reached adulthood, as well as their sisters, possibly carriers of a deleterious Bruton tyrosine kinase variant. Studies on motherhood outcomes in families with XLA are lacking.
Objective: We sought to investigate adherence to carrier status screening, interest in preconception and prenatal genetic counseling, and reproductive decisions in relatives with XLA.
Experiences and Perspectives of Female Employees Regarding Work-Family Balance Following Maternity Leave: A Cross-Sectional Survey in Southeastern Iran.
Int J Prev Med
December 2024
Health Services Management Research Centre, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Background: Work-family balance has emerged as one of the influencing factors for the physical and mental health of working mothers and their children.
Aims: The present study aimed to understand the experiences and perspectives of working mothers on maternity leave and return to work after childbirth. This cross-sectional survey was conducted in three major cities in southeastern Iran.
Cost-Effectiveness and Clinical Outcomes of Controlled Ovarian Stimulation With Follitropin Delta and Follitropin Alfa: A Retrospective Study.
Cureus
December 2024
Reproductive Medicine, Torch Clinic, Tokyo, JPN.
Aim: This study compared the cost-effectiveness of two recombinant follicle-stimulating hormones (rFSH) formulations, Follitropin Delta and Follitropin Alfa, in controlled ovarian stimulation using cumulative live birth rates as an efficacy indicator.
Methodology: This retrospective study was conducted across five clinics in Japan from April 2022 to December 2023, involving 446 first assisted reproductive technology (ART) cycles (200 with Follitropin Delta and 246 with Follitropin Alfa) were treated with rFSH monotherapy using either Follitropin Delta or Follitropin Alfa. We compared clinical outcomes such as cumulative pregnancy and live birth rates and analyzed cost-effectiveness using the cumulative live birth rates as the efficacy indicator and the incremental cost-effectiveness ratio (ICER).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!